hotspot -WSS

hotspot

author：fashion 2025-09-29 22:53:16 - browse：2162

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Pregnant women don't need prenatal multivitamins, study concludes

WSS

Medicare drug price negotiation continues, as pharma counteroffers

Pregnant women don't need prenatal multivitamins, study concludes

Wegovy leads to weight loss. Can it treat depression, too?

Ozempic has benefits for kidney disease as well as diabetes

Merck, Johnson & Johnson CEOs will testify on high drug prices

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

focus

hotspot

knowledge

Alkermes shareholders re

Boston competes with Raleigh

Peter Hotez and the public health issue of online harassment

Bernie Sanders is gearing up to subpoena pharma CEOs

Hollywood unions extend contract negotiations for actors

Pancreatic cancer early detection could be helped by AI

United colonoscopy coverage change 'may cost lives,' doctors say

Harvard's David Sinclair gets blowback over aging

Novavax promises a turnaround & Lilly roils the obesity market

The public health thinking behind the CDC’s new Covid guidance

explore

Families look for replacement for GSK asthma drug Flovent

The public health thinking behind the CDC’s new Covid guidance

Biden's 'march

White House pharmacy plagued with problems, investigation finds

Change Healthcare: What is it, why does its cyberattack matter?

Health Care Service Corp to buy Cigna Medicare Advantage plans

leisure time

hotspot

entertainment

hotspot